Is Lanadelumab safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Lanadelumab. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Minimal information available on the clinical use of lanadelumab during breastfeeding indicated no infant harm. Because lanadelumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] If lanadelumab is required by the mother, it is not a reason to discontinue breastfeeding. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]
Effects on the breastfed infant
An infant was breastfed (extent and duration not stated) by a mother with hereditary angioedema who was using lanadelumab every 3 weeks subcutaneously with no complications. At the age of 2 years, the child was diagnosed with hereditary angioedema but was otherwise healthy.[4]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Lanadelumab” (LM1414). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.